Prothena Corporation plc (NASDAQ:PRTA) Receives Consensus Recommendation of "Hold" from Analysts

Shares of Prothena Corporation plc (NASDAQ:PRTA - Get Free Report) have been given an average rating of "Hold" by the nine analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $31.50.

Several equities research analysts have commented on the company. Jefferies Financial Group cut Prothena from a "buy" rating to a "hold" rating and set a $6.00 target price on the stock. in a research note on Tuesday, May 27th. Piper Sandler cut their target price on Prothena from $110.00 to $81.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 27th. HC Wainwright cut their target price on Prothena from $30.00 to $14.00 and set a "buy" rating on the stock in a research note on Tuesday, May 27th. JMP Securities cut their target price on Prothena from $78.00 to $29.00 and set a "market outperform" rating on the stock in a research note on Tuesday, May 27th. Finally, Chardan Capital dropped their price objective on Prothena from $40.00 to $18.00 and set a "buy" rating on the stock in a research note on Tuesday, May 27th.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Public Employees Retirement System of Ohio acquired a new position in Prothena in the 2nd quarter valued at $256,000. Mogy Joel R Investment Counsel Inc. acquired a new stake in shares of Prothena during the 2nd quarter worth $126,000. Siren L.L.C. grew its holdings in shares of Prothena by 16.7% during the 1st quarter. Siren L.L.C. now owns 1,283,555 shares of the biotechnology company's stock worth $15,884,000 after purchasing an additional 183,715 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in shares of Prothena during the 1st quarter worth $230,000. Finally, Birchview Capital LP lifted its position in shares of Prothena by 9.3% during the 1st quarter. Birchview Capital LP now owns 332,974 shares of the biotechnology company's stock worth $4,121,000 after buying an additional 28,400 shares during the last quarter. 97.08% of the stock is owned by institutional investors and hedge funds.

Prothena Price Performance

NASDAQ:PRTA opened at $6.26 on Friday. Prothena has a fifty-two week low of $4.32 and a fifty-two week high of $25.42. The stock has a market capitalization of $336.98 million, a PE ratio of -3.01 and a beta of 0.01. The business's 50-day simple moving average is $6.02 and its 200-day simple moving average is $10.33.

Prothena (NASDAQ:PRTA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biotechnology company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.20). Prothena had a negative net margin of 79.94% and a negative return on equity of 21.61%. The business had revenue of $2.83 million for the quarter, compared to the consensus estimate of $8.18 million. During the same quarter last year, the firm earned ($1.34) EPS. The company's revenue for the quarter was up 5500.0% on a year-over-year basis. On average, research analysts expect that Prothena will post -4.04 earnings per share for the current year.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.